Literature DB >> 21126629

Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma.

Danijela Lekovic1, Predrag Miljic, Biljana Mihaljevic.   

Abstract

BACKGROUND: Primary mediastinal large B-cell lymphoma (PMBCL) is a rare subtype of diffuse large B-cell lymphoma, arising in the mediastinum. Compression of large mediastinal vessels is common in patients with PMBCL, predisposing these patients to venous thrombosis. The incidence of this complication is still unknown.
MATERIALS AND METHODS: We conducted a retrospective chart review of 42 consecutive patients diagnosed with PMBCL at a Clinic for hematology, Clinical Center of Serbia between 1999 and 2009 to identify the frequency and risk factors for venous thromboembolic disease (VTE) and its correlation with survival.
RESULTS: In the subgroup of patients with thrombosis (VTE subgroup) were 15/42 patients (35.7%): 14 patients had deep venous thrombosis and 1 had pulmonary embolism. Ten patients had a thrombosis at the moment of diagnosis PMBCL, while in five thrombosis occurred during the course of the disease. According to hemostasis variables, patients in the VTE subgroup had significantly higher fibrinogen (P=0.02) and D-Dimer (P<0.001). Also, patients in the VTE subgroup had significantly larger diameter of mediastinal tumor mass (P=0.01) and the incidence of syndrome venae cava superior (P=0.009). The median survival rate in the VTE subgroup was 45 months (95% CI; 22 to 68 months) while in the NVTE it was 93 (95% CI; 46 to 140 months), (log rank P=0.058).
CONCLUSIONS: VTE is a common complication in PMBCL patients and according to our results negatively influences survival. Use of antithrombotic prophylaxis may be considered together with chemotherapy, especially in those with bulky mediastinal tumor mass.
Copyright © 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21126629     DOI: 10.1016/j.thromres.2010.08.017

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  Venous-thromboembolism and associated health care utilization in elderly patients with diffuse large B cell lymphoma.

Authors:  Radhika Gangaraju; Elizabeth S Davis; Smita Bhatia; Kelly M Kenzik
Journal:  Cancer       Date:  2022-04-01       Impact factor: 6.921

2.  Less Intensive Regimens May Still Be Suitable for the Initial Treatment of Primary Mediastinal B-Cell Lymphoma in Resource-Limited Settings.

Authors:  Rodrigo Dolphini Velasques; Wellington F da Silva; Marcelo Bellesso; Vanderson Rocha; Juliana Pereira
Journal:  J Oncol       Date:  2022-06-06       Impact factor: 4.501

3.  Immune activation and inflammatory biomarkers as predictors of venous thromboembolism in lymphoma patients.

Authors:  Vladimir Otasevic; Biljana Mihaljevic; Natasa Milic; Dejana Stanisavljevic; Vojin Vukovic; Kristina Tomic; Jawed Fareed; Darko Antic
Journal:  Thromb J       Date:  2022-04-19

4.  Management of Primary Mediastinal B-Cell Lymphoma in Pregnancy.

Authors:  Sidra Khalid; Aariez Khalid; Hamed Daw; Praful Maroo
Journal:  Cureus       Date:  2018-02-21

5.  Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism.

Authors:  Sung Hee Lim; Sook-Young Woo; Seonwoo Kim; Young Hyeh Ko; Won Seog Kim; Seok Jin Kim
Journal:  Cancer Res Treat       Date:  2015-03-02       Impact factor: 4.679

6.  Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma.

Authors:  Joanna Rupa-Matysek; Lidia Gil; Marta Barańska; Dominik Dytfeld; Mieczysław Komarnicki
Journal:  Oncotarget       Date:  2018-04-20

7.  Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice.

Authors:  Joanna Rupa-Matysek; Katarzyna Brzeźniakiewicz-Janus; Lidia Gil; Zbigniew Krasiński; Mieczysław Komarnicki
Journal:  Cancer Med       Date:  2018-05-15       Impact factor: 4.452

8.  Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas.

Authors:  Jakub Svoboda; Steven M Bair; Daniel J Landsburg; Sunita Dwivedy Nasta; Sarah J Nagle; Stefan K Barta; Nadia Khan; Joanne Filicko-O'Hara; Sameh Gaballa; Lauren Strelec; Elise Chong; Sheryl Mitnick; Terease S Waite; Cara King; Hatcher Ballard; Matthew Youngman; James Gerson; John P Plastaras; Amit Maity; Agata M Bogusz; Stacy S Hung; Hisae Nakamura; Reza Nejati; Christian Steidl; Megan Lim; Marco Ruella; Stephen J Schuster
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 11.047

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.